Protection against Candidiasis by an Immunoglobulin G3 (IgG3) Monoclonal Antibody Specific for the Same Mannotriose as an IgM Protective Antibody
Open Access
- 1 March 2000
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 68 (3) , 1649-1654
- https://doi.org/10.1128/iai.68.3.1649-1654.2000
Abstract
We previously reported that a liposome-mannan vaccine (L-mann) ofCandida albicansinduces production of mouse antibodies that protect against disseminated candidiasis and vaginal infection. Immunoglobulin M (IgM) monoclonal antibody (MAb) B6.1, specific for aC. albicanscell surface β-1,2-mannotriose, protects mice against both infections. Another IgM MAb, termed B6, which is specific for a different cell surface mannan epitope, does not protect against disseminated candidiasis. The B6.1 epitope is displayed homogeneously over the entire cell surface, compared to a patchy distribution of the B6 epitope. To determine if protection is restricted to an IgM class of antibody, we tested an IgG antibody. MAb C3.1 was obtained from L-mann-immunized mice. By results of sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis, capture enzyme-linked immunosorbent assay, and immunodiffusion tests, MAb C3.1 is an IgG3 isotype. By epitope inhibition assays, we determined that MAb C3.1 is specific for same mannotriose as MAb B6.1. As expected by the results of the inhibition assays, immunofluorescence microscopy showed that the C3.1 epitope is distributed on the yeast cell surface in a pattern identical to that of the B6.1 epitope. Kidney CFU and mean survival times of infected mice pretreated with MAb C3.1 indicated that the antibody enhanced resistance of mice against disseminated candidiasis. Mice in pseudoestrus that were given MAb C3.1 prior to vaginal infection developed fewer vaginalCandidaCFU than control animals that received buffered saline instead of the antibody. The finding that an IgG3 antibody is protective is consistent with our hypothesis that epitope specificity and complement activation are related to the ability of an antibody to protect against candidiasis.Keywords
This publication has 45 references indexed in Scilit:
- Antibodies against Candida: potential therapeutics?Trends in Microbiology, 1996
- Interleukin‐12 profoundly up‐regulates the synthesis of antigen‐specific complement‐fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivoEuropean Journal of Immunology, 1995
- Existence of Branched Side Chains in the Cell Wall Mannan of Pathogenic Yeast, Candida albicansPublished by Elsevier ,1995
- Variable Region-Identical Monoclonal Antibodies of Different IgG Subclass Directed to Pseudomonas aeruginosa Lipopolysaccharide O-Specific Side Chain Function DifferentlyThe Journal of Infectious Diseases, 1993
- Sequential nuclear magnetic resonance assignment of .beta.-1,2-linked mannooligosaccharides isolated from the phosphomannan of the pathogenic yeast Candida albicans NIH B-792 strainBiochemistry, 1992
- Antibodies Elicited by a Cryptococcus neoformans-Tetanus Toxoid Conjugate Vaccine Have the Same Specificity as Those Elicited in InfectionThe Journal of Infectious Diseases, 1992
- Monoclonal antibodies in the therapy of experimental neonatal group B streptococcal diseaseClinical Immunology and Immunopathology, 1992
- Intermolecular cooperativity: a clue to why mice have IgG3?Immunology Today, 1992
- Characterisation of mouse monoclonal antibodies produced by immunisation with a single serotype component of a polyvalent Pseudomonas aeruginosa vaccineJournal of Medical Microbiology, 1986
- Characterization of Monoclonal Antibodies Protecting Mice against Rickettsia rickettsiiThe Journal of Infectious Diseases, 1985